

# Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 2, 2026

## Treatment of SSRI-resistant Depression in Adolescents (TORDIA)

RRID:SCR\_008831

Type: Tool

---

### Proper Citation

Treatment of SSRI-resistant Depression in Adolescents (TORDIA) (RRID:SCR\_008831)

---

### Resource Information

**URL:** <http://www.nimh.nih.gov/funding/clinical-trials-for-researchers/practical/tordia/treatment-of-ssri-resistant-depression-in-adolescents-tordia.shtml>

**Proper Citation:** Treatment of SSRI-resistant Depression in Adolescents (TORDIA) (RRID:SCR\_008831)

**Description:** A multi-site, clinical research study examining treatment options for teens whose depression has not improved after one adequate trial of a selective serotonin reuptake inhibitor (SSRI), a type of antidepressant. The purpose of the study is to determine how best to treat adolescents with depression that is resistant to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy. The TORDIA study aims to develop useful clinical guidelines for the care and management of adolescent depression. Adolescents ages 12 to 18, currently taking a prescribed selective serotonin reuptake inhibitor (SSRI) and still experiencing depression, participate in a 12-week randomized treatment study that includes one of four conditions: (1) switching to an alternative SSRI, (2) switching to a different non-SSRI antidepressant, (3) switching to an alternative SSRI and receiving cognitive behavioral therapy (CBT), or (4) switching to a different non-SSRI antidepressant and receiving CBT. This is a double-blind study, which means that neither the participant nor the clinical staff will know which of the three possible medications has been assigned. Participants who respond to the assigned treatment will receive 12 additional weeks of the same treatment. Those who do not appear to be getting better will be offered 12 weeks of an alternative, individualized treatment plan based on each participant's particular needs. All participants will receive follow-up psychiatric evaluations for 12 months after the 12-week continuation phase of the study, regardless of treatment adherence. For more information visit, <http://www.clinicaltrials.gov/ct2/show/NCT00018902?term=clinical+trial+AND+treatment+of+ssri-resistant+AND+depression+AND+TORDIA+AND+study&rank=1>

**Abbreviations:** TORDIA

**Synonyms:** Treatment of SSRI-resistant Depression in Adolescents

**Resource Type:** clinical trial, data or information resource, portal, research forum portal, topical portal, disease-related portal

**Defining Citation:** [PMID:20478877](#)

**Keywords:** young human, adolescent, depression, depressive disorder, clinical trial, selective serotonin reuptake inhibitor, antidepressant, nct00018902, drug, fluoxetine, venlafaxine, behavioral therapy, cognitive behavioral therapy, citalopram, treatment

**Related Condition:** Depressive Disorder, Resistant to the first SSRI antidepressant

**Funding:** NIMH

**Resource Name:** Treatment of SSRI-resistant Depression in Adolescents (TORDIA)

**Resource ID:** SCR\_008831

**Alternate IDs:** nlx\_146237

**Record Creation Time:** 20220129T080249+0000

**Record Last Update:** 20260801T190404+0000

---

## Ratings and Alerts

No rating or validation information has been found for Treatment of SSRI-resistant Depression in Adolescents (TORDIA).

No alerts have been found for Treatment of SSRI-resistant Depression in Adolescents (TORDIA).

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We have not found any literature mentions for this resource.